Choline, Ketones and Purines: Cracking the Metabolic Enigmas of Soft Tissue Sarcoma

Soft tissue sarcomas (STS), a diverse group of mesenchymal malignancies, present a diagnostic mystery due to their heterogeneity and the restrictions of traditional methods.Invasive biopsies offer a stationary outline of a dynamic process, failing to capture the tumor's evolving metabolic landscape.This opinion conceives that untargeted metabolomics, specifically when applied to liquid biopsies, offers an exemplar shift in STS diagnostics.By cross-examining the circulating metabolome, we can gain realtime insights into tumor behavior, treatment response, and metastatic potential.This method moves beyond static genetic markers, revealing a metabolic illusion that replicates the tumor's adaptation to its microenvironment.Important metabolites, such as ketone bodies, choline derivatives, and purines, emerge as potential biomarkers, offering a preview into altered energy metabolism, membrane dynamics, and cell proliferation.Integrating metabolomic data with genetic profiling provides a universal understanding of STS biology, paving the way for earlier detection, personalized therapies, and improved patient outcomes.A call for collaborative action is essential to harness the full potential of untargeted metabolomics in the fight against STS.